We are live on ! Find out more
ORIAU

Orion Biotech Opportunities Corp. Units

Delisted

ORIAU was delisted on the 25th of April, 2023.

14 hedge funds and large institutions have $33.2M invested in Orion Biotech Opportunities Corp. Units in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

22% less funds holding

Funds holding: 1814 (-4)

41% less capital invested

Capital invested by funds: $56.2M → $33.2M (-$23.1M)

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 6

Holders
14
Holders Change
-4
Holders Change %
-22.22%
% of All Funds
0.22%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
1
Increased
Reduced
6
Closed
5
Calls
Puts
Net Calls
Net Calls Change

ORIAU Hedge Fund Activity: Q1 2022 in Review

14 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Orion Biotech Opportunities Corp. Units (ORIAU) for Q1 2022, worth a combined $33.2M — down 41% from $56.2M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of ORIAU and 1 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 0 added.

The largest buyer was Wolverine Asset Management, opening a new position worth an estimated $9.81K. The largest seller was Linden Advisors, exiting entirely with an estimated $6.93M sold.

  • 14 institutional investors held Orion Biotech Opportunities Corp. Units (ORIAU) as of Q1 2022, down from 18 in Q4 2021.
  • Funds reported $33.2M of Orion Biotech Opportunities Corp. Units stock for Q1 2022, down 41% quarter-over-quarter.
  • 1 fund opened new Orion Biotech Opportunities Corp. Units positions in Q1 2022 and 5 closed out, a net change of -4 holders.
  • The largest Orion Biotech Opportunities Corp. Units buyer in Q1 2022 was Wolverine Asset Management, an estimated $9.81K added.
  • The largest Orion Biotech Opportunities Corp. Units seller in Q1 2022 was Linden Advisors, an estimated $6.93M sold.

Based on aggregated 13F filings for Q1 2022.